Improvements in Systemic Therapies for Advanced Malignant Mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best...

Full description

Bibliographic Details
Main Authors: Chiara Deiana, Francesca Fabbri, Simona Tavolari, Andrea Palloni, Giovanni Brandi
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/24/13/10415
_version_ 1797591634544689152
author Chiara Deiana
Francesca Fabbri
Simona Tavolari
Andrea Palloni
Giovanni Brandi
author_facet Chiara Deiana
Francesca Fabbri
Simona Tavolari
Andrea Palloni
Giovanni Brandi
author_sort Chiara Deiana
collection DOAJ
description Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best interpret the data available on these drugs. Furthermore, we focused on promising treatments under investigation, such as immunotherapy with targets different from anti-PD-1/PD-L1 inhibitors, vaccines, target therapies, and metabolism-based strategies.
first_indexed 2024-03-11T01:40:05Z
format Article
id doaj.art-750ce89a06b74d45af63641dd4298ac9
institution Directory Open Access Journal
issn 1661-6596
1422-0067
language English
last_indexed 2024-03-11T01:40:05Z
publishDate 2023-06-01
publisher MDPI AG
record_format Article
series International Journal of Molecular Sciences
spelling doaj.art-750ce89a06b74d45af63641dd4298ac92023-11-18T16:37:51ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-06-0124131041510.3390/ijms241310415Improvements in Systemic Therapies for Advanced Malignant MesotheliomaChiara Deiana0Francesca Fabbri1Simona Tavolari2Andrea Palloni3Giovanni Brandi4Medical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, ItalyMalignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best interpret the data available on these drugs. Furthermore, we focused on promising treatments under investigation, such as immunotherapy with targets different from anti-PD-1/PD-L1 inhibitors, vaccines, target therapies, and metabolism-based strategies.https://www.mdpi.com/1422-0067/24/13/10415mesotheliomaadvanced mesotheliomasystemic therapiesnovel approachesimmunotherapytarget therapy
spellingShingle Chiara Deiana
Francesca Fabbri
Simona Tavolari
Andrea Palloni
Giovanni Brandi
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
International Journal of Molecular Sciences
mesothelioma
advanced mesothelioma
systemic therapies
novel approaches
immunotherapy
target therapy
title Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title_full Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title_fullStr Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title_full_unstemmed Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title_short Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
title_sort improvements in systemic therapies for advanced malignant mesothelioma
topic mesothelioma
advanced mesothelioma
systemic therapies
novel approaches
immunotherapy
target therapy
url https://www.mdpi.com/1422-0067/24/13/10415
work_keys_str_mv AT chiaradeiana improvementsinsystemictherapiesforadvancedmalignantmesothelioma
AT francescafabbri improvementsinsystemictherapiesforadvancedmalignantmesothelioma
AT simonatavolari improvementsinsystemictherapiesforadvancedmalignantmesothelioma
AT andreapalloni improvementsinsystemictherapiesforadvancedmalignantmesothelioma
AT giovannibrandi improvementsinsystemictherapiesforadvancedmalignantmesothelioma